$809 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 132 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SPDR S&P 500 ETF Trustput | $39,404,000 | – | 200,000 | +100.0% | 4.87% | – | |
| New | Health Care Select Sector SPDRput | $31,028,000 | – | 485,500 | +100.0% | 3.83% | – | |
| B108PS | New | ACTAVIS PLC | $29,460,000 | – | 122,100 | +100.0% | 3.64% | – |
| ABBV | New | ABBVIE INC | $23,309,000 | – | 403,550 | +100.0% | 2.88% | – |
| ISRL | New | Isramco Negev 2 LP | $22,136,000 | – | 103,111,944 | +100.0% | 2.74% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $16,847,000 | – | 150,000 | +100.0% | 2.08% | – |
| VRX | New | VALEANT PHARMACEUTICALS INTE | $12,930,000 | – | 98,550 | +100.0% | 1.60% | – |
| New | VALEANT PHARMACEUTICALS INTEcall | $12,753,000 | – | 97,200 | +100.0% | 1.58% | – | |
| MNKKQ | New | MALLINCKRODT PLC | $12,255,000 | – | 135,940 | +100.0% | 1.51% | – |
| UTHR | New | UNITED THERAPEUTICS CORP | $11,429,000 | – | 88,840 | +100.0% | 1.41% | – |
| ICL | New | Israel Chemicals Ltd | $9,977,000 | – | 1,380,000 | +100.0% | 1.23% | – |
| ESLT | New | Elbit Systems Ltdord | $8,974,000 | – | 144,759 | +100.0% | 1.11% | – |
| New | ASTRAZENECA PLC-SPONS ADRsponsored adr | $8,573,000 | – | 120,000 | +100.0% | 1.06% | – | |
| GCVRZ | New | SANOFIright 12/31/2020 | $7,689,000 | – | 67,960 | +100.0% | 0.95% | – |
| New | ASTRAZENECA PLC-SPONS ADRcall | $6,937,000 | – | 97,100 | +100.0% | 0.86% | – | |
| MDAS | New | MEDA AB-A SHS | $6,103,000 | – | 433,889 | +100.0% | 0.75% | – |
| New | Apple Inc | $5,042,000 | – | 50,045 | +100.0% | 0.62% | – | |
| ITRN | New | Ituran Location and Control Lt | $4,861,000 | – | 231,115 | +100.0% | 0.60% | – |
| AMAG | New | AMAG PHARMACEUTICALS INC | $4,794,000 | – | 150,230 | +100.0% | 0.59% | – |
| MYL | New | MYLAN INC | $4,417,000 | – | 97,100 | +100.0% | 0.55% | – |
| ASPX | New | AUSPEX PHARMACEUTICALS INC | $4,237,000 | – | 165,074 | +100.0% | 0.52% | – |
| AGTC | New | APPLIED GENETIC TECHNOLOGIES | $3,922,000 | – | 210,724 | +100.0% | 0.48% | – |
| UNP | New | Union Pacific Corp | $3,503,000 | – | 32,312 | +100.0% | 0.43% | – |
| TKAI | New | TOKAI PHARMACEUTICALS INC | $3,482,000 | – | 230,000 | +100.0% | 0.43% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $3,447,000 | – | 14,565 | +100.0% | 0.43% | – |
| PRQR | New | PROQR THERAPEUTICS NV | $3,438,000 | – | 200,000 | +100.0% | 0.42% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $3,354,000 | – | 490,355 | +100.0% | 0.41% | – |
| VFC | New | VF Corp | $3,163,000 | – | 47,900 | +100.0% | 0.39% | – |
| RDUS | New | RADIUS HEALTH INC | $3,150,000 | – | 150,000 | +100.0% | 0.39% | – |
| SLXP | New | SALIX PHARMACEUTICALS LTD | $3,125,000 | – | 20,000 | +100.0% | 0.39% | – |
| XLRN | New | ACCELERON PHARMA INC | $3,024,000 | – | 100,000 | +100.0% | 0.37% | – |
| SLB | New | Schlumberger Ltd | $2,928,000 | – | 28,790 | +100.0% | 0.36% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $2,770,000 | – | 87,924 | +100.0% | 0.34% | – |
| OTIC | New | OTONOMY INC | $2,666,000 | – | 111,085 | +100.0% | 0.33% | – |
| NICE | New | NICE Systems Ltdsponsored adr | $2,622,000 | – | 64,542 | +100.0% | 0.32% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $2,516,000 | – | 194,200 | +100.0% | 0.31% | – |
| CPRX | New | CATALYST PHARMACEUTICAL PART | $2,276,000 | – | 685,500 | +100.0% | 0.28% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL CO | $2,146,000 | – | 223,330 | +100.0% | 0.26% | – |
| New | ARENA PHARMACEUTICALS INC | $2,095,000 | – | 500,000 | +100.0% | 0.26% | – | |
| RLYP | New | RELYPSA INC | $2,048,000 | – | 97,100 | +100.0% | 0.25% | – |
| SNA | New | Snap-on Inc | $1,949,000 | – | 16,100 | +100.0% | 0.24% | – |
| KITE | New | KITE PHARMA INC | $1,937,000 | – | 67,970 | +100.0% | 0.24% | – |
| MA | New | MasterCard Inccl a | $1,922,000 | – | 26,000 | +100.0% | 0.24% | – |
| BLUE | New | BLUEBIRD BIO INC | $1,916,000 | – | 53,405 | +100.0% | 0.24% | – |
| ZFGN | New | ZAFGEN INC | $1,908,000 | – | 97,100 | +100.0% | 0.24% | – |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $1,899,000 | – | 293,533 | +100.0% | 0.24% | – |
| New | ALDER BIOPHARMACEUTICALS INC | $1,902,000 | – | 150,000 | +100.0% | 0.24% | – | |
| New | Mankind Corpput | $1,773,000 | – | 300,000 | +100.0% | 0.22% | – | |
| ACRX | New | ACELRX PHARMACEUTICALS INC | $1,591,000 | – | 289,849 | +100.0% | 0.20% | – |
| EARS | New | AURIS MEDICAL AG | $1,111,000 | – | 191,300 | +100.0% | 0.14% | – |
| ORPN | New | BIO BLAST PHARMA LTD | $1,091,000 | – | 150,000 | +100.0% | 0.14% | – |
| PTN | New | PALATIN TECHNOLOGIES INC | $1,009,000 | – | 1,084,466 | +100.0% | 0.12% | – |
| AFMD | New | AFFIMED NV | $945,000 | – | 150,000 | +100.0% | 0.12% | – |
| New | ALCOBRA LTDcall | $866,000 | – | 56,100 | +100.0% | 0.11% | – | |
| ZSPH | New | ZS PHARMA INC | $811,000 | – | 20,682 | +100.0% | 0.10% | – |
| PRTA | New | PROTHENA CORP PLC | $663,000 | – | 29,907 | +100.0% | 0.08% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $286,000 | – | 22,700 | +100.0% | 0.04% | – |
| BCLI | New | BRAINSTORM CELL THERAPEUTICS | $265,000 | – | 63,331 | +100.0% | 0.03% | – |
| MCUR | New | MACROCURE LTD | $51,000 | – | 7,100 | +100.0% | 0.01% | – |
| AUXL | New | AUXILIUM PHARMACEUTICALS INC | $30,000 | – | 1,000 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2014-11-20
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.